CPC A61K 31/138 (2013.01) [A61K 31/145 (2013.01); A61K 31/352 (2013.01); A61K 31/40 (2013.01); A61K 31/41 (2013.01); A61K 31/4178 (2013.01); A61K 31/4184 (2013.01); A61K 31/437 (2013.01); A61K 31/7056 (2013.01); A61K 31/7088 (2013.01); A61K 38/085 (2013.01); A61K 38/48 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/6803 (2017.08); A61K 47/6807 (2017.08); A61K 47/6851 (2017.08); A61K 47/6855 (2017.08); C07K 16/18 (2013.01); C12N 15/113 (2013.01); A61K 2039/505 (2013.01); C12N 2310/14 (2013.01); C12N 2310/351 (2013.01); C12N 2310/50 (2013.01)] | 20 Claims |
1. A method of treating breast cancer in a subject, comprising:
administering to the subject an anti-PAX2 composition,
wherein the composition comprises an effective amount of an anti-PAX2 agent,
wherein the anti-PAX2 agent is an antagonist of PAX2; and
wherein the anti-PAX2 agent is not a STAT3 inhibitor.
|